Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review
JM Sanders, ML Monogue, TZ Jodlowski, JB Cutrell - Jama, 2020 - jamanetwork.com
Importance The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an …
Compassionate use of remdesivir for patients with severe Covid-19
J Grein, N Ohmagari, D Shin, G Diaz… - … England Journal of …, 2020 - Mass Medical Soc
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA
polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided …
polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided …
[HTML][HTML] Liver injury in COVID-19: the hepatic aspect of the respiratory syndrome—what we know so far
P Anirvan, P Bharali, M Gogoi… - World journal of …, 2020 - ncbi.nlm.nih.gov
The 2019 novel coronavirus disease (COVID-19) pandemic due to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global public health …
syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global public health …
Therapeutic effectiveness of interferon-α2b against COVID-19: the cuban experience
R Pereda, D González, HB Rivero… - Journal of Interferon & …, 2020 - liebertpub.com
A prospective observational study was conducted for assessing the therapeutic efficacy of
interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus …
interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus …
Employee well-being: new challenges in post-COVID-19 times
A Reizer - Psychological well-being and behavioral interactions …, 2022 - books.google.com
The COVID-19 period emphasized the vulnerability employees and employers face, and
was characterized as a traumatic period throughout the world. However, it also accelerated …
was characterized as a traumatic period throughout the world. However, it also accelerated …
A review of medications used to control and improve the signs and symptoms of COVID-19 patients
In December 2019, an unprecedented outbreak of pneumonia associated with a novel
coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The …
coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The …
[PDF][PDF] Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus
Abstract Novel coronavirus disease (COVID-19) infection is a global pandemic, of high
infectivity, variable mortality, with currently no established treatment. This review …
infectivity, variable mortality, with currently no established treatment. This review …
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
J Cunningham, A DArminio Monforte… - New England Journal …, 2020 - escholarship.org
BACKGROUND: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA
polymerases, has shown in vitro activity against SARS-CoV-2. METHODS: We provided …
polymerases, has shown in vitro activity against SARS-CoV-2. METHODS: We provided …
Manejo y tratamiento en pacientes con enfermedad por coronavirus 2019 (COVID-19) y sus implicaciones endocrinologías.
B Peña-Aparicio… - Revista Mexicana de …, 2020 - search.ebscohost.com
Los casos confirmados de infección por el coronavirus 2 del síndrome respiratorio agudo
grave (SARS-CoV-2) deben tratarse con condiciones efectivas de aislamiento y protección …
grave (SARS-CoV-2) deben tratarse con condiciones efectivas de aislamiento y protección …
COVID-19 pandemic: Dental considerations and review of literature
The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to …
respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to …